| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma
|
Franken, Margreet G.
|
|
|
123 |
C |
p. 58-71
|
artikel
|
| 2 |
Corrigendum to ‘Prediction of melanoma evolution in melanocytic nevi via artificial intelligence: A call for prospective data’ [Eur J Cancer, 119 (September 2019) Pages 30–34]
|
Sondermann, Wiebke
|
|
|
123 |
C |
p. 171
|
artikel
|
| 3 |
Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion
|
Hendriks, Lizza E.L.
|
|
|
123 |
C |
p. 28-35
|
artikel
|
| 4 |
Dietary 2-deoxy-D-glucose impairs tumour growth and metastasis by inhibiting angiogenesis
|
Singh, Saurabh
|
|
|
123 |
C |
p. 11-24
|
artikel
|
| 5 |
Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials
|
Ronellenfitsch, Ulrich
|
|
|
123 |
C |
p. 101-111
|
artikel
|
| 6 |
DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial
|
Sundar, Raghav
|
|
|
123 |
C |
p. 48-57
|
artikel
|
| 7 |
Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study
|
Walter, Thomas
|
|
|
123 |
C |
p. 92-100
|
artikel
|
| 8 |
Health-related quality of life in patients with fully resected BRAF V600 mutation–positive melanoma receiving adjuvant vemurafenib
|
Schadendorf, Dirk
|
|
|
123 |
C |
p. 155-161
|
artikel
|
| 9 |
Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors
|
Vozy, Aurore
|
|
|
123 |
C |
p. 112-115
|
artikel
|
| 10 |
Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden
|
Satzger, Imke
|
|
|
123 |
C |
p. 83-91
|
artikel
|
| 11 |
Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial
|
Sharma, Atul
|
|
|
123 |
C |
p. 162-170
|
artikel
|
| 12 |
Negative phase III trials announce the need for biomarkers in sarcoma
|
Lee, Alexander TJ.
|
|
|
123 |
C |
p. 81-82
|
artikel
|
| 13 |
Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France
|
Moya-Plana, A.
|
|
|
123 |
C |
p. 1-10
|
artikel
|
| 14 |
Overestimated treatment effects in randomised phase II trials: What's up doctor?
|
Michiels, Stefan
|
|
|
123 |
C |
p. 116-117
|
artikel
|
| 15 |
Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study
|
Forster, Martin D.
|
|
|
123 |
C |
p. 36-47
|
artikel
|
| 16 |
Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma
|
Mesia, Ricard
|
|
|
123 |
C |
p. 138-145
|
artikel
|
| 17 |
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer
|
Grossi, Francesco
|
|
|
123 |
C |
p. 72-80
|
artikel
|
| 18 |
Revocation of the conditional marketing authorisation of a cancer medicine: The olaratumab experience
|
Herold, Ralf
|
|
|
123 |
C |
p. 25-27
|
artikel
|
| 19 |
Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study
|
Ducreux, Michel
|
|
|
123 |
C |
p. 146-154
|
artikel
|
| 20 |
The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications
|
Soldevilla, B.
|
|
|
123 |
C |
p. 118-129
|
artikel
|
| 21 |
Valuing preferences for treating screen detected ductal carcinoma in situ
|
Bromley, Hannah L.
|
|
|
123 |
C |
p. 130-137
|
artikel
|
Tijdschrift beschrijving